[{"orgOrder":0,"company":"Incyte Corporation","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"INCB000928","moa":"\nALK2","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Incyte Corporation","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Incyte Corporation \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Incyte Corporation \/ Undisclosed"},{"orgOrder":0,"company":"CRISPR Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2020","type":"Inapplicable","leadProduct":"Exagamglogene Autotemcel","moa":"CD34","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CRISPR Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CRISPR Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CRISPR Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Spark Therapeutics, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2018","type":"Inapplicable","leadProduct":"SPK-8016","moa":"Coagulation factor VIII (F8)","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Spark Therapeutics, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spark Therapeutics, Inc \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Spark Therapeutics, Inc \/ Undisclosed"},{"orgOrder":0,"company":"CSL Behring","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2020","type":"Inapplicable","leadProduct":"CSL312","moa":"Coagulation factor XII (F12)","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"CSL Behring","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Behring \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"CSL Behring \/ Undisclosed"},{"orgOrder":0,"company":"UT Southwestern Medical Center","sponsor":"AMAG Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2014","type":"Inapplicable","leadProduct":"Evening Primrose Oil","moa":"Erythropoietin receptor","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"UT Southwestern Medical Center","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UT Southwestern Medical Center \/ AMAG Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"UT Southwestern Medical Center \/ AMAG Pharmaceuticals"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Coagulation Factor VIIa","moa":"F7a||Factor VIII","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"Catalyst Biosciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Marzeptacog Alpha","moa":"Factor VIII","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Catalyst Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Catalyst Biosciences \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Catalyst Biosciences \/ Undisclosed"},{"orgOrder":0,"company":"International Partnership for Microbicides","sponsor":"Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dapivirine","moa":"Human immunodeficiency virus type 1 reverse transcriptase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"International Partnership for Microbicides","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health","highestDevelopmentStatusID":"7","companyTruncated":"International Partnership for Microbicides \/ Gansu Provincial Maternal and Child Health Care Hospital | National Institutes of Health"},{"orgOrder":0,"company":"Regeneron Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"REGN7257","moa":"IL-2 receptor","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Regeneron Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Regeneron Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Regeneron Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Jubilant Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"JBI-802","moa":"LSD1\/HDAC6","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Jubilant Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jubilant Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Jubilant Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Prolong Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2015","type":"Inapplicable","leadProduct":"Anf-Rho","moa":"Rho kinase","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Prolong Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Prolong Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Prolong Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Crescent Biopharma","sponsor":"University of Michigan","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Uproleselan","moa":"Selectin E","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Crescent Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crescent Biopharma \/ University of Michigan","highestDevelopmentStatusID":"7","companyTruncated":"Crescent Biopharma \/ University of Michigan"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Alexey Danilov","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Entospletinib","moa":"Tyrosine-protein kinase SYK","graph1":"Hematology","graph2":"Phase I\/ Phase II","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gilead Sciences \/ Alexey Danilov","highestDevelopmentStatusID":"7","companyTruncated":"Gilead Sciences \/ Alexey Danilov"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Check COS database
Check USDMF database

Contact Us
PharmaScopic.com

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Jubilant Therapeutics

U.S.A

ISPE Annual Meeting

Not Confirmed

02

International Partnership for Microbicides

U.S.A

ISPE Annual Meeting

Not Confirmed

03

AbFero Pharmaceuticals

U.S.A

ISPE Annual Meeting

Not Confirmed

04

Catalyst Biosciences

U.S.A

ISPE Annual Meeting

Not Confirmed

05

Incyte Corporation

U.S.A

ISPE Annual Meeting

Not Confirmed

06

Regeneron Pharmaceuticals

U.S.A

ISPE Annual Meeting

Not Confirmed

07

CRISPR Therapeutics

U.S.A

ISPE Annual Meeting

Not Confirmed

08

CSL Behring

U.S.A

ISPE Annual Meeting

Not Confirmed

09

X4 Pharmaceuticals

U.S.A

ISPE Annual Meeting

Not Confirmed

10

Spark Therapeutics, Inc

U.S.A

ISPE Annual Meeting

Not Confirmed

1
2